期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

BRAFV600E在甲状腺乳头状癌与桥本甲状腺炎相关性中的研究

Study of BRAFV600E in the correlation between papillary thyroid carcinoma and Hashimoto＆#39;s thyroiditis
原文传递
导出
摘要 目的 研究BRAFV600E在甲状腺乳头状癌与桥本甲状腺炎中的表达,探讨甲状腺乳头状癌与桥本甲状腺炎的相关性.方法 北京空军总医院2012年1月-2014年6月经病理证实的甲状腺石蜡标本,甲状腺乳头状癌40例、桥本甲状腺炎20例、甲状腺乳头状癌伴桥本甲状腺炎20例、甲状腺腺瘤20例,采用免疫组化（Envision法）检测BRAFV600E的表达并进行半定量分析,比较其在各组中的表达差异.结果 甲状腺乳头状癌BRAFV600E阳性率为77.5％ （31/40）,桥本甲状腺炎BRAFV600E阳性率为45.0％（9/20,P=0.012）.甲状腺乳头状癌伴桥本甲状腺炎的肿瘤组织区域BRAFV600E阳性率为70.0％（14/20）,与单纯甲状腺乳头状癌的阳性率差异无统计学意义（P=0.156）;而桥本甲状腺炎区域BRAFV600E阳性率为55％（11/20,P=0.527）,与单纯桥本甲状腺炎BRAFV600E的阳性率差异亦无统计学意义（P＞0.05）.甲状腺乳头状癌有转移者BRAFV600E阳性率（88.2％,15/17）高于甲状腺乳头状癌未转移者（69.5％,16/23,P=0.030）.甲状腺腺瘤中未检测到BRAFV600E.结论 甲状腺乳头状癌和桥本甲状腺炎均呈现较高的BRAFV600E突变率. Objective To explore the expression of BRAFV600E in papillary thyroid carcinoma and Hashimoto＇s thyroiditis,and investigate the correlation between papillary thyroid carcinoma and Hashimoto＇s thyroiditis.Methods The paraffin embedded tissue specimens of pathologically confirmed thyroid disease during 2012.1-2014.6 in the Air Force General Hospital were collected,including 40 cases of papillary thyroid carcinoma,20 cases of Hashimoto＇ s thyroiditis,20 cases of papillary thyroid carcinoma with Hashimoto＇s thyroiditis and 20 cases of thyroid adenoma.Immunohistochemistry （Envision method） was used to detect the expression of BRAFV600E and semi quantitative analysis was used to compare the difference of different thyroid diseases.Results The positive rate of BRAFV600E was 77.5% （31/40） in papillary thyroid carcinoma and 45% （9/20） in Hashimoto＇ s thyroiditis （P =0.012）.In papillary thyroid carcinoma with Hashimoto＇s thyroiditis,the positive rate of BRAFV600E in thyroid papillary carcinoma tissue was 70.0% （14/20）,which was not different from thyroid papillary carcinoma （P =0.156） ; and the positive rate of BRAFV600E in Hashimoto＇s thyroiditis tissue was 55.0% （11/20）,which was not different from Hashimoto＇s thyroiditis（P =0.527）.The positive rate of BRAFVE600 in metastatic papillary thyroid carcinoma was 88.2% （15/17）,which was higher than that in papillary thyroid carcinoma without metastasis （69.5%,16/23,P =0.030）.There was no expression of BRAFV600E in thyroid adenoma.Conclusion Papillary thyroid carcinoma and Hashimoto＇s thyroiditis have a higher BRAFV600E mutation rate.
作者 于亚静 杨彩哲 刘明 任力 王良宸 曹亚蕊
机构地区 空军总医院内分泌科
出处 《国际内分泌代谢杂志》 北大核心 2014年第6期375-378,F0003,共5页 International Journal of Endocrinology and Metabolism
关键词 甲状腺乳头状癌 桥本甲状腺炎 BRAFV600E Thyroid papillary carcinoma Hashimoto＆#39 s thyroiditis BRAFV600E
分类号 R736.1 [医药卫生—肿瘤]
  • 相关文献

参考文献14

  • 1Enewold L,Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005 [ J ]. Cancer Epidemiol Biomarkers Prey, 2009, 18 (3) :784-791.
  • 2Paulson LM,Shindo ML, Schuff KG. Role of chronic lymphoeytic thyroiditis in central node metastasis of papillary thyroid carcino- ma[ J]. Otolaryngol Head Neck Surg,2012,147 ( 3 ) :444-449.
  • 3He G,Zhao B,Zhang X,et al. Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma[J]. Oncol Lett,2014,7(2) : 439-443.
  • 4江晓燊,解乃昌.甲状腺乳头状癌BRAF V600E突变蛋白质的表达及意义[J].广东医学,2013,34(6):931-933. 被引量：6
  • 5Sclafani F, Gonzalez D, Cunningham D, et al. RAS mutations and cetuximab in locally advanced rectal Cancer: results of the EX- PERT-C trial[J]. Eur J Cancer,2014,50(8) :1430-1436.
  • 6Gibault L, Cazes A, Narjoz C, et al. Molecular profiling of non- small cell lung cancer[ J]. Rev Pneumol Clin, 2014,70 (1-2) : 47-62.
  • 7Kebebew E, Weng J, Bauer J,et al. Tile prevalence and prognostic value of BRAF mutation in thyroid encer[ J]. Ann Surg,2007, 246 ( 3 ) :466-470 ; discussion 470-471.
  • 8Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications [ J ]. Endoer Rev, 2007,28(7 ) :742-762.
  • 9Franzoni A, Dima M, D' agostino M, et al. Prohibitin is overex- pressed in papillary thyroid cm'cinomas bearing the BRAF (V600E) mutation [ J ]. Thyroid,2009,19 (3) :247-255.
  • 10Faustino A, Couto JP,P6pulo H, et al. mTOR pathway overactiva- tion in BRAF mutated papillary thyroid carcinoma [ J ]. J Clin Endocrinol Metab ,2012,97 (7) : E1139-E1149.

二级参考文献27

  • 1NIKIFOROV Y E. Molecular diagnostics of thyroid tumors [ J ]. Arch Pathol Lab Med, 2011, 135(5) : 569 -577.
  • 2XING M. BRAF mutation in thyroid cancer [ J ]. Endocr Relat Cancer, 2005, 12(2): 245-262.
  • 3LEE J H, LEE E S, KIM Y S, et al. Clinicopathologic signifi- cance of BRAF V600E mutation in papillary carcinomas of the thy- roid: a meta - analysis[J]. Cancer, 2007, 110( 1 ) : 38 -46.
  • 4PALONA I, NAMBA H, MITSUTAKE N, et al. BRAF V600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation [ J ]. Endocrinology, 2006, 147 ( 12 ) : 5699 - 5707.
  • 5XING M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications[ J]. Endocr Rev, 2007, 28 (7) : 742 - 762.
  • 6ELISEI R, UGOLINI C, VIOLA D, et al. BRAF(V6OOE) muta- tion and outcome of patients with papillary thyroid carcinoma: a 15 -year median follow -up study[Jl. J Clin Endocrinol Metab, 2008, 93 (10) : 3943 - 3949.
  • 7XING M, WESTRA W H, TUFANO R P, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer [ J]. J Clin Endocrinol Metab, 2005, 90(12) : 6373 -6379.
  • 8GUAN H, JI M, BAO R, et al. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer[ J]. J Clin Endocrinol Metab, 2009, 94(5) : 1612 -1617.
  • 9Pellegriti G,Frasca F,Regalbuto C. Worldwide increasing incidence of thyroid cancer:update on epidemiology and risk factors[J].Journal of Cancer Epidemiol,2013.965212.
  • 10Siegel R,Naishadham D,Jemal A. Cancer statistics for Hispanics/Latinos,2012[J].CA:A Cancer Journal for Clinicians,2012.10-29.

共引文献55

国际内分泌代谢杂志
2014年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部